Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Patients without commercial coverage or whose plans exclude anti-obesity medications face the full list price
Results Study participant characteristics A total of 3,171 male and female participants were included in the STEP 1 and STEP 2 trials
Prior efforts to treat obesity demonstrate that sustained weight reduction is a Herculean task--thus it may be the case that GLP-1 agents will need to be administered chronically to sustain anti-obesity benefits
The role of carnitine in male infertility
Vitamin B2 (Riboflavin), Reduced Glutathione, CoQ10 (Ubiquinone), PQQ, Alpha Lipoic Acid
Trial Data Sparks Interest: Phase 3 results for retatrutide reveal substantial weight reductions up to 28 percent at higher doses, with many participants achieving outcomes comparable to surgical interventions
